BioGx now offers 11 CE-marked infectious disease tests that run on Becton Dickinson's BD Max platform.
The firm has made two separate senior notes offerings in euros and British pounds, and it plans to use the proceeds to redeem other outstanding notes.
The firm raised its full fiscal year 2018 revenue and adjusted earnings per share guidance.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
The PAXgene Blood ccfDNA tube enables clinical laboratories to stabilize samples when they cannot be processed on the day they were collected.
The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.
The firm saw revenue growth across all segments, with diagnostic systems revenues increasing 14 percent.
The BD MAX Check-Points CPO assay detects common carbapenemase-producing organisms in less than 2.5 hours.
The investment bank noted that Hologic could be the "biggest beneficiary from tax reform" in its coverage with a potential 8 percent benefit to earnings per share.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.